PDCD1 and neoplasm: Interestingly, these vaccines not only inhibited the tumor growth and improved the clinical outcome, but also demonstrated an enhanced the clinical response in combination with anti-PD1 antibodies, resulting in tumor clearance in approximately 75% of mice [111].